Iterative Metal Artifact Reduction in Head and Neck CT Facilitates Tumor Visualization of Oral and Oropharyngeal Cancer Obscured by Artifacts From Dental Hardware.


Journal

Academic radiology
ISSN: 1878-4046
Titre abrégé: Acad Radiol
Pays: United States
ID NLM: 9440159

Informations de publication

Date de publication:
12 2023
Historique:
received: 08 02 2023
revised: 02 04 2023
accepted: 07 04 2023
medline: 1 12 2023
pubmed: 14 5 2023
entrez: 13 5 2023
Statut: ppublish

Résumé

The purpose of this study was to evaluate the diagnostic utility of iterative metal artifact reduction (iMAR) in computed tomography (CT)-imaging of oral and oropharyngeal cancers when obscured by dental hardware artifacts and to determine the most appropriate iMAR settings for this purpose. The study retrospectively enrolled 27 patients (8 female, 19 male; mean age 64±12.7years) with histologically confirmed oral or oropharyngeal cancer obscured by dental artifacts in contrast-enhanced CT. Raw CT data were reconstructed with ascending iMAR strengths (levels 1/2/3/4/5) and one reconstruction without iMAR (level 0). For subjective analysis, two blinded radiologists rated tumor visualization and artifact severity on a five-point Likert scale. For objective analysis, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and artifact index (AI) were determined. iMAR reconstructions improved the subjective image quality of tumor edge and contrast, and the objective parameters of tumor SNR and CNR, reaching their optimum at iMAR levels 4 and 5 (P<.001). AI decreased with iMAR reconstructions reaching its minimum at iMAR level 5 (P<.001). Tumor detection rates increased 2.4-fold with iMAR 5, 2.1-fold with iMAR 4, and 1.9-fold with iMAR 3 compared to reconstructions without iMAR. Disadvantages such as algorithm-induced artifacts increased significantly with higher iMAR strengths (P<.05), reaching a maximum with iMAR 5. iMAR significantly improves CT imaging of oral and oropharyngeal cancers, as confirmed by both subjective and objective measures, with best results at highest iMAR strengths.

Identifiants

pubmed: 37179206
pii: S1076-6332(23)00199-X
doi: 10.1016/j.acra.2023.04.007
pii:
doi:

Substances chimiques

Metals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2962-2972

Informations de copyright

Copyright © 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matthias Stefan May reports a relationship with Siemens Healthcare that includes: speaking and lecture fees. Wolfgang Wuest reports a relationship with Siemens Healthcare that includes: speaking and lecture fees. Jan-Peter Roth reports a relationship with Siemens Healthcare that includes: speaking and lecture fees. Michael Uder reports a relationship with Siemens Healthcare that includes: speaking and lecture fees. Christian Hofmann reports a relationship with Siemens Healthcare that includes: employment. Bernhard Schmidt reports a relationship with Siemens Healthcare that includes: employment.

Auteurs

Nadine Bayerl (N)

Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany (N.B., M.S.M., J.-P.R., M.U., S.E.). Electronic address: nadine.bayerl@fau.de.

Matthias Stefan May (MS)

Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany (N.B., M.S.M., J.-P.R., M.U., S.E.).

Wolfgang Wuest (W)

Institute of Radiology, Martha-Maria Hospital Nürnberg, Nürnberg, Germany (W.W.).

Jan-Peter Roth (JP)

Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany (N.B., M.S.M., J.-P.R., M.U., S.E.).

Manuel Kramer (M)

RNZ - Radiologisch-Nuklearmedizinisches Zentrum, Lauf a.d. Pegnitz, Germany (M.K.).

Christian Hofmann (C)

Siemens Healthcare GmbH, Computed Tomography, Forchheim, Germany (C.H., B.S.).

Bernhard Schmidt (B)

Siemens Healthcare GmbH, Computed Tomography, Forchheim, Germany (C.H., B.S.).

Michael Uder (M)

Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany (N.B., M.S.M., J.-P.R., M.U., S.E.).

Stephan Ellmann (S)

Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany (N.B., M.S.M., J.-P.R., M.U., S.E.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH